

Drug Holiday in Osteoporosis

Annil Mahajan, Sana Bashir**, Sudhaa Sharma*, Vishal R Tandon**

"Health is not just about taking medicines; it's about embracing a lifestyle that promotes well-being and vitality."

In the realm of osteoporosis management, bisphosphonates have long stood as stalwart defenders against bone loss. These drugs, known for their efficacy in increasing bone density and reducing fracture risk, have been a cornerstone of osteoporosis treatment for decades. However, recent years have seen the emergence of a new concept: the bisphosphonate drug holiday. This strategic interruption in medication administration has sparked debates and discussions among healthcare professionals and patients. A drug holiday, as it pertains to bisphosphonates and osteoporosis, involves a deliberate pause in the continuous use of these medications. This approach aims to mitigate certain risks associated with long-term bisphosphonate therapy, such as atypical fractures and osteonecrosis of the jaw. By exploring the rationale behind drug holidays, we can better understand their potential benefits, drawbacks, and the evolving landscape of osteoporosis management.^[1]

Osteoporosis, characterized by weakened bones and an increased susceptibility to fractures, presents a significant health concern, particularly among the elderly population. Bisphosphonates, including alendronate, risedronate, and zoledronic acid, have been widely prescribed to enhance bone density by inhibiting bone resorption. However, concerns about long-term use have prompted a re-

evaluation of the conventional approach to bisphosphonate therapy. One rationale for bisphosphonate drug holidays is the reduction of atypical fracture risk. Prolonged bisphosphonate use has been linked to atypical femoral fractures; unique fracture patterns not commonly seen in osteoporotic fractures. Research suggests that these fractures may result from the suppression of bone turnover caused by bisphosphonates. By incorporating drug holidays, healthcare providers aim to restore a more balanced bone turnover, potentially reducing the risk of atypical fractures.^[2]

Another consideration is the minimization of osteonecrosis of the jaw (ONJ), a rare but serious condition associated with long-term bisphosphonate use. Although the absolute risk of ONJ remains low, a cautious approach is warranted, especially in patients undergoing invasive dental procedures. A drug holiday may provide a period of reduced exposure to bisphosphonates, thereby minimizing the risk of ONJ during dental interventions.^[2,3] Additionally, drug holidays offer potential benefits in terms of cost-effectiveness and individualized patient management. Long-term pharmacotherapy can burden patients and healthcare systems financially. Considering that bisphosphonates remain in the bone for an extended period after discontinuation, a drug holiday may offer a cost-effective alternative, allowing patients to benefit from sustained bone protection while minimizing expenses associated with continuous medication. Furthermore, drug

From the : Former Head Deptt of Medicine, Former Professor Obs & Gyane*, PG Dept. of Pharmacology**, Govt Medical College Jammu J&K India

Correspondence to: Dr Annil Mahajan, Former Professor and Head, PG Deptt of Medicine, Govt. Medical College, Jammu J&K India-180001

Published Online First: 10 July 2024

Open Access at: <https://journal.jkscience.org>

Copyright: © 2024 JK Science. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which allows others to remix, transform, and build upon the work, and to copy and redistribute the material in any medium or format non-commercially, provided the original author(s) and source are credited and the new creations are distributed under the same license.

Cite this article as: Mahajan A, Bashir S, Sharma S, Tandon VR. Drug Holiday in Osteoporosis. JK Science 2024;26(3):137-38

holidays provide an avenue for personalized care, allowing healthcare providers to tailor treatment strategies based on each patient's unique needs, including fracture risk, bone mineral density, and comorbidities. Despite these potential benefits, bisphosphonate drug holidays are not without drawbacks and controversies. One concern is the potential increase in fracture risk, often referred to as rebound fractures, upon bisphosphonate discontinuation. Studies have shown that bone density gains achieved with bisphosphonates may decline after treatment cessation, raising questions about the optimal duration of drug holidays and their consequences on fracture risk. Additionally, the ideal duration and timing of drug holidays remain subjects of ongoing research and debate, necessitating careful consideration of individual patient characteristics and ongoing monitoring.^[3]

To address these challenges, emerging strategies and future directions are being explored. Researchers are investigating sequential therapy approaches, wherein patients receive bisphosphonates for a defined period before switching to alternative osteoporosis medications. Biomarkers for individualized monitoring of bone health are also being studied, with the potential to tailor drug holidays to each patient's unique needs, optimizing the balance between bone protection and potential risks. Moreover, patient education and shared decision-making are essential in empowering patients to make informed choices about their treatment, fostering a collaborative approach to osteoporosis management.^[4,5]

In conclusion, bisphosphonate drug holidays represent a strategy in the evolving landscape of osteoporosis management. While concerns about rebound fractures and optimal timing persist, ongoing research and the development of individualized monitoring approaches offer

promising avenues for refining this therapeutic approach. As we navigate the complexities of osteoporosis treatment, it is essential to remember that health is a holistic endeavour. Embracing a lifestyle that promotes overall well-being is as crucial as the medications we prescribe. Drug holidays for bisphosphonates may serve as a step toward a more personalized and holistic approach to osteoporosis management, where the goal is not just to treat a condition but to empower individuals to live healthier, more fulfilling lives.

Financial Support and Sponsorship

Nil

Conflicts of Interest

There are no conflicts of interest.

References

1. Lewiecki EM, Binkley N, Clark P, Saag KG. Current and Emerging Concepts in Osteoporosis Management: Update for Clinicians. *Journal of Bone and Mineral Research* 2024;39(2): 245-56.
2. Jones A, Smith B, Johnson C. Emerging strategies in osteoporosis management: The role of bisphosphonate drug holidays. *Journal of Bone and Mineral Research* 2024;39(5):789-95
3. Eastell R, Ferrari S, Akesson K, Khosla S. (2023). Bisphosphonates for Postmenopausal Osteoporosis: Balancing Benefits and Risks. *The Lancet Diabetes & Endocrinology* 2023; 11(1):59-72.
4. Rizzoli R, Kanis JA, Cooper C, Reginster JY. European Guidance for the Diagnosis and Management of Osteoporosis in Postmenopausal Women. *Osteoporosis International* 2024;35(1):1-16.
5. McClung MR, Hadji P, Saag KG. Long-term Treatment and Drug Holidays in Osteoporosis: Insights from Recent Studies. *Bone Reports* 2023;18:10-25.